ALX Oncology (ALXO) announced the appointment of Jeff Knight as chief development and operating officer, effective April 13. Most recently, he served as chief development and operating officer at Crinetics (CRNX).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Appoints Jeff Knight to Lead Development
- ALX Oncology initiated with an Overweight at Wells Fargo
- Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation
- ALX Oncology price target raised to $4 from $2 at H.C. Wainwright
- Alx Oncology Earnings Call Highlights Biomarker Momentum